Purple Biotech Shares Owned By Institutions vs. Cash Per Share
KTOV Stock | ILA 7.20 0.20 2.70% |
For Purple Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Purple Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Purple Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Purple Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Purple Biotech over time as well as its relative position and ranking within its peers.
Purple |
Purple Biotech Cash Per Share vs. Shares Owned By Institutions Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Purple Biotech's current stock value. Our valuation model uses many indicators to compare Purple Biotech value to that of its competitors to determine the firm's financial worth. Purple Biotech is currently regarded as number one stock in shares owned by institutions category among its peers. It also is currently regarded as number one stock in cash per share category among its peers fabricating about 0.33 of Cash Per Share per Shares Owned By Institutions. The ratio of Shares Owned By Institutions to Cash Per Share for Purple Biotech is roughly 3.06 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Purple Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Purple Biotech's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Purple Cash Per Share vs. Shares Owned By Institutions
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Purple Biotech |
| = | 1.22 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Purple Biotech |
| = | 0.40 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Purple Cash Per Share Comparison
Purple Biotech is currently under evaluation in cash per share category among its peers.
Purple Biotech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Purple Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Purple Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Purple Biotech's change in net profit over the period of time. It can combine multiple indicators of Purple Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Kitov Pharma Ltd, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. The company was formerly known as Kitov Pharmaceuticals Holdings Ltd. and changed its name to Kitov Pharma Ltd in January 2018. KITOV PHARMA operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 9 people.
Purple Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Purple Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Purple Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Purple Biotech's important profitability drivers and their relationship over time.
Use Purple Biotech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Purple Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Purple Biotech will appreciate offsetting losses from the drop in the long position's value.Purple Biotech Pair Trading
Purple Biotech Pair Trading Analysis
The ability to find closely correlated positions to Purple Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Purple Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Purple Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Purple Biotech to buy it.
The correlation of Purple Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Purple Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Purple Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Purple Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Purple Biotech position
In addition to having Purple Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Tech Funds Thematic Idea Now
Tech Funds
Funds or Etfs that invest in companies involved in research, development, testing, or distribution of technologically based goods and services. The Tech Funds theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Tech Funds Theme or any other thematic opportunities.
View All Next | Launch |
Additional Information and Resources on Investing in Purple Stock
When determining whether Purple Biotech is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Purple Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Purple Biotech Stock. Highlighted below are key reports to facilitate an investment decision about Purple Biotech Stock:Check out Correlation Analysis. For information on how to trade Purple Stock refer to our How to Trade Purple Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
To fully project Purple Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Purple Biotech at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Purple Biotech's income statement, its balance sheet, and the statement of cash flows.